Botulinum toxin type a within function-oriented management of post-stroke spasticity: a narrative review
- 1School of Health Science and Engineering, University of Shanghai for Science and Technology
Abstract
Post-stroke spasticity (PSS) is a heterogeneous complication of stroke that affects motor recovery, care needs, pain, positioning, and participation in daily life. Current management frameworks commonly stratify patients by time since stroke, but disease duration alone does not capture differences in neural mechanisms, residual voluntary control, functional priorities, or response to intervention. This narrative review searched PubMed, the Cochrane Library, and Wanfang databases from inception to May 2026, prioritizing randomized controlled trials, prospective cohort studies, systematic reviews, real-world studies, Goal Attainment Scaling research, the Upper Limb International Spasticity cohort series, best-practice guidance, and clinical trials including BEST and InTENSE. We synthesize evidence that PSS heterogeneity can be understood across central and peripheral mechanisms, temporal trajectories, and active versus passive functional consequences. Available studies suggest that active and passive functional goals differ in baseline functional profiles, outcome assessment, treatment response, and intervention requirements. However, patients sharing a functional goal type may still differ in residual voluntary control, neural and non-neural contributors to movement restriction, pain, mobility, and care dependency. Botulinum toxin type A is well aligned with focal tone reduction and passive goals, including pain relief, hygiene, and limb positioning. It may also support contracture-prevention strategies when modifiable neural muscle overactivity remains, whereas active functional gains usually require preserved motor potential and integration with task-oriented training, rehabilitation, and adjunctive modalities. We propose that functional goal type should complement time-based staging as a decision dimension rather than serve as a complete clinical phenotype. This combined framework may better align patient selection, intervention matching, outcome assessment, and longitudinal treatment planning. Prospective goal-stratified studies and standardized assessment tools are needed to test its clinical utility.
Related
- Active Function Improvement with Repeated Injections of Botulinum Toxin A in Upper Limb Spasticity: A Longitudinal Analysis from the ULIS-III Study.
- Improving detection of candidates for botulinum toxin therapy in spasticity: an interprofessional screening approach
- Adjunctive extracorporeal shock wave therapy after botulinum toxin type A injection for post-stroke spasticity: a systematic review and three-level meta-analysis
- Adolescent Endometriosis: From Clinical Management to an Early Recognition and Prevention-Oriented Paradigm-A Narrative Review.
- Baclofen for Spasticity in Multiple Sclerosis: A Comprehensive Narrative Review
BibTeX
@article{su2026botulinum,
title = {{Botulinum toxin type a within function-oriented management of post-stroke spasticity: a narrative review}},
author = {Baoling Su and Yating Huang and Xiaotong Li and Kun Wang and Bing Bao},
journal = {Frontiers in Neurology},
year = {2026},
month = oct,
doi = {10.3389/fneur.2026.1921220},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1921220/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Botulinum toxin type a within function-oriented management of post-stroke spasticity: a narrative review
AU - Baoling Su
AU - Yating Huang
AU - Xiaotong Li
AU - Kun Wang
AU - Bing Bao
PY - 2026
DA - 2026/10/12
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1921220
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1921220/full
AB - Post-stroke spasticity (PSS) is a heterogeneous complication of stroke that affects motor recovery, care needs, pain, positioning, and participation in daily life. Current management frameworks commonly stratify patients by time since stroke, but disease duration alone does not capture differences in neural mechanisms, residual voluntary control, functional priorities, or response to intervention. This narrative review searched PubMed, the Cochrane Library, and Wanfang databases from inception to May 2026, prioritizing randomized controlled trials, prospective cohort studies, systematic reviews, real-world studies, Goal Attainment Scaling research, the Upper Limb International Spasticity cohort series, best-practice guidance, and clinical trials including BEST and InTENSE. We synthesize evidence that PSS heterogeneity can be understood across central and peripheral mechanisms, temporal trajectories, and active versus passive functional consequences. Available studies suggest that active and passive functional goals differ in baseline functional profiles, outcome assessment, treatment response, and intervention requirements. However, patients sharing a functional goal type may still differ in residual voluntary control, neural and non-neural contributors to movement restriction, pain, mobility, and care dependency. Botulinum toxin type A is well aligned with focal tone reduction and passive goals, including pain relief, hygiene, and limb positioning. It may also support contracture-prevention strategies when modifiable neural muscle overactivity remains, whereas active functional gains usually require preserved motor potential and integration with task-oriented training, rehabilitation, and adjunctive modalities. We propose that functional goal type should complement time-based staging as a decision dimension rather than serve as a complete clinical phenotype. This combined framework may better align patient selection, intervention matching, outcome assessment, and longitudinal treatment planning. Prospective goal-stratified studies and standardized assessment tools are needed to test its clinical utility.
SN - 1664-2295
ER -